LII Jornadas SOLACI

19º Región Centroamérica y el Caribe

8, 9 y 10 de Octubre, 2025

San José de Costa Rica
COSTA RICA

Valvulopatía tricuspídea intervención percutánea

Dr Márcio Montenegro
Instituto Estadual de Cardiologia Aloysio de Castro
Rio de Janeiro - Brasil

CONFLITO INTERÉS

- PROCTOR P&F

The Role of Imaging in the Evolution of Tricuspid Regurgitation Diagnosis and Management

2DE and 3DE



Valve, Ventricles and Atrium



Multi-modality Imaging

Anatomy

Etiology



Quantitation



Right Heart Size & Function

RV-PA Coupling



Outcomes

Parameter	↓Outcomes
TR Severity	≥Mild TR
3DE RV Basal Diameter	>40 mm
TAPSE	<17 mm
FAC	<35%
RVFWLS	>-22%
3D RVEF	<45%
Effective RVEF	<20%
TAPSE/PASP	<0.41 mm/mmHg

Transcatheter Device Therapies

Screening and Guidance





Outcomes



Central Illustration: Advances in Percutaneous Tricuspid Valve Treatment





Arq Bras Cardiol: Imagem cardiovasc. 2024;37(4):e20240088

STVRR: surgical tricuspid valve replacement or repair; ICDL: intracardiac device lead; TEER: transcatheter edge-to-edge repair; TTVR: transcatheter tricuspid valve replacement; THCVI: transcatheter heterotopic caval valve implantation; RV: right ventricle; TR: tricuspid regurgitation.

Heterotopic devices

Goal: to reduce the venous congestion and backflow associated with TR for symptomatic improvement

Annulus

Goal: reducing the annular dilation
- Restrictive Annuloplasty
- Direct Annuloplasty

Tricuspid valve replacement

Goal: implantation of bioprosthetic valve within the tricuspid annulus



Leaflet

Goal: restoration of coaptation and reduction of regurgitant orifice area.

Coaptation enhancement

Goal: to fill or eliminate the coaptation defect


Heterotopic replacement
Tricento
Tricvalve
Leaflet devices
Triclip
Pascal
Mistral
Annuloplasty
Cardioband
Millipede
MIA
T. NISI
Orthotopic replacement
GATE
Evoque
Cardiovalve
Intrepid
Lux
Trisol
Valve-in-Valve/Valve-in-Ring
Valve-in-Valve
Valve-in-Ring

Transcatheter Tricuspid Valve Therapies Landscape

Transcatheter Edge to Edge Repair

- Devices: TriClip, PASCAL
- Favorable Indications

1. Small leaflet coaptation gap (<7 mm)
2. "True" tricuspid (3 leaflets) morphology
3. Confined prolapse or flail of any leaflet
4. Jet location: Anteroseptal


TriClip


PASCAL

Tricuspid Valve Replacement

- Devices: Evoque, LuxValve, GATE
- Favorable Indications

1. Greater leaflet coaptation gap (>8.5 mm)
2. Valve tethering (more than moderate)
3. Previous Tricuspid Valve Replacement (ViV)
4. Thickened leaflets (heavily calcified)


LuxValve


Evoque


GATE

Annuloplasty

- Devices: Cardioband
- Favorable Indications

1. Dilated tricuspid annulus as the key pathophysiological mechanism
2. Valve tethering preferably mild
3. Jet location: Central


Cardioband

Heterotopic Caval Valve Implantation

- Devices: Tricento, TricValve
- Favorable Indications

1. Venous congestion – significant backflow in caval veins
2. Not suitable for orthotopic valve implantation
3. Appropriate cava anatomy-size


TricValve

K Dimitriadis et al *Life* 13:1417; 2023

Screening for Transcatheter Tricuspid Valve Intervention

TriSelect Study
Northwestern (Chicago), Bad Oeynhausen, Cologne

N=547



- **62%** Transcatheter Edge-to-Edge Repair
- **38%** Transcatheter valve annuloplasty



Montefiore
New York

N=50



- **50%** TTVR
- **47%** TEER
- **3%** Other (Caval Valve)

Future Innovations and Clinical Needs

- Broad Toolbox of TTVI Therapies (e.g., TTVR)
- Earlier Referral & Volume Optimization
- Imaging Innovation (e.g., 4D-ICE, AI)
- Alternative Permanent Pacing Strategies

TR DISEASE STAGING AND POST-TREATMENT SURVIVAL



CENTRAL ILLUSTRATION: Transcatheter Tricuspid Valve Repair Safe and Effective in Real-World Population

Real-World Population

- Mean age: 78.9 years
- Mean LVEF 55.8%
- NYHA functional class III/IV: 88%
- Male: 44%
- Prior HF Hospitalization: 40.3%
- Baseline KCCQ score: 44.52

Reduction in TR at 30 Days



Safety Profile at 30 Days

Major Adverse Event	2.7%
• Cardiovascular mortality	0.8%
• Myocardial infarction	0.0%
• Stroke	0.4%
• New onset renal failure	1.4%
• Endocarditis requiring surgery	0.0%
• Nonelective CV surgery for device-related AE	0.2%

MAEs adjudicated by independent clinical events committee

Lurz P, et al. J Am Coll Cardiol. 2023;82(4):281-291.



IT ATRIOGENICA – XTW-AS XT-

CRÉDITO PARA CLEV

TTVR CHALLENGES



CENTRAL ILLUSTRATION: 1-Year EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation

EVOQUE Transfemoral Tricuspid Replacement

1-Year Clinical and Echocardiographic Outcomes







27 patients with severe TR
treated with the EVOQUE system
7 sites (Canada, Europe, U.S.)
May 2019 to July 2020

All-cause mortality: 7%
HF hospitalization: 7%
New pacemaker: 7% within 30 days,
4% beyond 30 days

Sustained improvement in NYHA functional class as well as improvement in TR degree suggesting that the EVOQUE System is a promising treatment option for this population

Webb, J.G. et al. J Am Coll Cardiol Intv. 2022;15(5):481-491.

CENTRAL ILLUSTRATION: 30-Day Results of the TRISCEND Study With the EVOQUE System



Kodali, S. et al. J Am Coll Cardiol Intv. 2022;15(5):471-480.

The Lux Valve PLUS TTVR System

Self-Adaptive Braided Ring

The "self-adaptive leak-proof braided ring" effectively aims to decrease post-procedural perivalvular leaks caused by annular dilation.

Multi-Dimensional Fixation

The "interventricular septal anchoring" technology enhances the traditional concept of radial support force fixation.

Trans-Jugular Delivery

Flexible and retrievable low-pro
delivery system allows valve ro
achieve perfect alignment on t
tricuspid annulus.

The LuX Valve PLUS Travel II: Study Design

PRIMARY OBJECTIVE:

To evaluate the acute and long-term safety and performance of the LuX-Valve Plus system in patients with at least severe tricuspid regurgitation

TRIAL OVERSIGHT

- Echocardiographic core lab
- Clinical events committee
- Data safety monitoring board



1-Year Cumulative All-Cause Mortality



All-cause mortality: 4.17%

- 1-patient died of a suspected cerebral infarction
- 1-patient died of a lung infection by COVID-19
- 2-patients complications related to falling



LUX VALVE CASE 9 – CLEVERSON ZUKOVSKI

PRIMEIRA TRICVALVE NO BRASIL



CENTRAL ILLUSTRATION: 6-Month Outcomes of the TricValve System for Severe TR: TRICUS EURO Study (N = 35)



Estévez-Loureiro R, et al. J Am Coll Cardiol Intv. 2022;15(13):1366-1377.

marciojmontenegro@gmail.com

MARCIO MONTENEGRO

@MarciMonteg

MUCHAS GRACIAS POR SÚ ATENCIÓN!

Dr Márcio Montenegro
Instituto Estadual de Cardiologia Aloysio de Castro
Rio de Janeiro - Brasil

TRATAMIENTO PERCUTÁNEO DE LA INSUFICIENCIA TRICUSPÍDEA: INNOVACIONES Y PERSPECTIVAS

LI Jornadas SOLACI
16° Región Cono Sur
7, 8 y 9 de mayo 2025
Montevideo, URUGUAY

Tricuspid valve transcatheter interventions



Real life world experience

312 patients with severe or greater symptomatic TR underwent TTVI and were included in the registry across 18 centers

The International Multicenter TriValve Registry

Which Patients Are Undergoing Transcatheter Tricuspid Repair?

Outcomes After Current Transcatheter Tricuspid Valve Intervention

Mid-Term Results From the International TriValve Registry



Taramasso M. JACC cardiovascular intervention , 2017 & 2018